What did @jonathan_odom actually say?
Jonathan is three weeks into a self-described 90-day body transformation using two compounds: "Retta" (retatrutide, a GLP-1/GIP/glucagon triple agonist peptide) and "incholomaphine" (almost certainly enclomiphene, a selective estrogen receptor modulator used off-label to raise endogenous testosterone). This week he is increasing his retatrutide dose to "25 units, which is around 2.5 milligrams." He also consumed somewhere between 10 and 30 drinks in a single day, stalled on weight loss for the week, and is now adding Goli apple cider vinegar gummies to his protocol after a tip from "Graham." He is targeting sub-240 pounds before December.
Credit where it is due: he was transparent about the binge drinking and acknowledged it likely caused his stall. That kind of honesty is rare in transformation content.
Does the science back this up?
Retatrutide has genuine clinical momentum, but it is still in trials. Enclomiphene has modest evidence for raising LH and testosterone. The apple cider vinegar claim is where the evidence gets thin fast.
Retatrutide (LY3437943) is a triple incretin agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. A phase 2 trial published by Jastreboff et al. (2023, New England Journal of Medicine) showed participants losing up to 24.2% of body weight over 48 weeks at the highest dose, which is a larger signal than semaglutide or tirzepatide in comparable trial windows. That is legitimately impressive data. However, that trial used pharmaceutical-grade compound under strict clinical supervision. What Jonathan is injecting is almost certainly a compounded peptide from a gray-market or telehealth source, and compounded retatrutide is not FDA-approved or bioequivalent to any approved product.
Enclomiphene has small but real evidence. A study by Kim et al. (2013, BJU International) showed it raised serum testosterone in hypogonadal men without suppressing sperm production the way exogenous testosterone does. But pairing it with a GLP-1 class peptide, while also doing heavy alcohol bingeing, is an untested combination with no safety data.
Apple cider vinegar for weight loss: a 2009 trial by Kondo et al. (Bioscience, Biotechnology, and Biochemistry) showed modest reductions in body weight in obese Japanese subjects, but the effect size was small (about 1-2 kg over 12 weeks). Goli gummies are not the same as the acetic acid doses studied. The "hack" framing is not supported by the literature.
What did they get wrong (or right)?
His unit-to-milligram conversion is approximately right, but his framing of the stack is missing important context. The alcohol binge is a more serious clinical problem than he treated it.
On the math: 25 units on a standard U-100 insulin syringe is 0.25 mL. If the peptide is reconstituted at a standard 10 mg per mL concentration, that is 2.5 mg. That conversion is roughly correct, but concentration varies by compounding pharmacy, which means his actual dose could be higher or lower without him knowing.
On the alcohol: GLP-1 receptor agonists slow gastric emptying significantly. Drinking heavily while on a GLP-1 class drug increases the risk of aspiration, severe nausea, vomiting, and dangerous blood sugar fluctuations. A 2022 review by Becker et al. (Alcohol and Alcoholism) flagged that GLP-1 agonists may actually reduce alcohol cravings in some patients, but that is not a license to binge. Thirty drinks is a medically serious event regardless of peptide use.
- Got right: honest about the setback and that it was his fault.
- Got wrong: treating a 30-drink day as a minor footnote when on an active peptide protocol.
- Got wrong: presenting apple cider vinegar gummies as a credible addition to an already aggressive stack.
- Unverifiable: whether his compounded retatrutide is dosed or formulated accurately.
What should you actually know?
Retatrutide is not approved by the FDA. Enclomiphene has limited but real evidence. Combining either with heavy alcohol is not studied and carries real risk.
Retatrutide does not yet have an approved indication. The phase 2 data is promising, but phase 3 trials are ongoing. People sourcing it through compounding pharmacies or peptide vendors are using an unregulated product with no guaranteed purity, potency, or sterility. That is not a small caveat.
Enclomiphene is sometimes prescribed off-label by testosterone optimization clinics for men who want to raise testosterone while preserving fertility. It is not a "testosterone booster" in the supplement sense. It is a pharmaceutical compound. Calling it that undersells both its mechanism and its risks.
If you are considering any GLP-1 class peptide for weight loss, the conversation belongs in a clinical setting with labs, a prescriber, and proper titration. Content like this is entertaining and often honest, but it is not a protocol you should replicate. The lack of a control group, medical supervision, or verified dosing makes any results Jonathan sees impossible to attribute cleanly to either compound.